PMID- 33073291 OWN - NLM STAT- MEDLINE DCOM- 20220214 LR - 20220214 IS - 1537-6613 (Electronic) IS - 0022-1899 (Linking) VI - 223 IP - 12 DP - 2021 Jun 15 TI - Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. PG - 2080-2089 LID - 10.1093/infdis/jiaa662 [doi] AB - BACKGROUND: Hepatitis B surface antigen (HBsAg) loss is an ideal goal for chronic hepatitis B patients. Antiretroviral therapy (ART) in hepatitis B virus/human immunodeficiency virus-1 (HBV/HIV-1)-coinfected patients can lead to hepatic flare (HF) caused by immune reconstitution-induced inflammatory syndrome (IRIS). Here, we investigated the impact of IRIS-HF on HBsAg loss. METHODS: This was a retrospective study of 58 HBV/HIV-1-coinfected subjects HBsAg-positive for >/=6 months before ART initiation and followed for >/=1 year (median 9.9 years) after ART initiation. We examined humoral factors in sera from healthy volunteers, HIV-monoinfected patients, and HBV/HIV-1-coinfected patients with IRIS-HF or acute hepatitis B infection. RESULTS: During ART, HBsAg loss was observed in 20 of 58 HBV/HIV-1-coinfected patients (34.5%). Of the 58 patients, 15 (25.9%) developed IRIS-HF within 12 months of ART initiation. HBsAg loss was more frequent among patients who developed IRIS-HF (11/15, 73.3%) than those who did not (9/43, 20.9%). Multivariate analysis showed IRIS-HF was an independent predictor of subsequent HBsAg loss. Younger age and higher baseline HBV DNA titer were associated with IRIS-HF. Elevation of sCD163, not CXCL9, CXC10, CXCXL11, or CXCL13, was observed at IRIS-HF. CONCLUSIONS: IRIS-HF was associated with HBsAg loss in HBV/HIV-1-coinfected patients. CI - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. FAU - Yoshikawa, Shiori AU - Yoshikawa S AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Yoshio, Sachiyo AU - Yoshio S AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Yoshida, Yuichi AU - Yoshida Y AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Tsutsui, Yuriko AU - Tsutsui Y AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Kawai, Hironari AU - Kawai H AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Yamazoe, Taiji AU - Yamazoe T AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Mori, Taizo AU - Mori T AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Osawa, Yosuke AU - Osawa Y AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Sugiyama, Masaya AU - Sugiyama M AD - Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Iwamoto, Masashi AU - Iwamoto M AD - Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan. FAU - Watashi, Koichi AU - Watashi K AD - Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan. FAU - Kawaguchi, Takumi AU - Kawaguchi T AD - Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. FAU - Akita, Tomoyuki AU - Akita T AD - Department of Epidemiology, Infectious Disease Control and Prevention, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Tanaka, Junko AU - Tanaka J AUID- ORCID: 0000-0002-5669-4051 AD - Department of Epidemiology, Infectious Disease Control and Prevention, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Kikuchi, Yoshimi AU - Kikuchi Y AD - AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. FAU - Mizokami, Masashi AU - Mizokami M AD - Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Oka, Shinichi AU - Oka S AD - AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. FAU - Kanto, Tatsuya AU - Kanto T AD - Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan. FAU - Gatanaga, Hiroyuki AU - Gatanaga H AD - AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Infect Dis JT - The Journal of infectious diseases JID - 0413675 RN - 0 (Anti-HIV Agents) RN - 0 (DNA, Viral) RN - 0 (Hepatitis B Surface Antigens) SB - IM MH - *Anti-HIV Agents/therapeutic use MH - *Coinfection/immunology/virology MH - DNA, Viral MH - *HIV Infections/complications/drug therapy MH - HIV-1 MH - Hepatitis B Surface Antigens/blood MH - Hepatitis B virus/genetics MH - *Hepatitis B, Chronic/complications MH - Humans MH - *Immune Reconstitution Inflammatory Syndrome MH - Retrospective Studies OTO - NOTNLM OT - HBV/HIV-1 OT - antiretroviral therapy OT - chemokine OT - chronic hepatitis OT - functional cure EDAT- 2020/10/20 06:00 MHDA- 2022/02/15 06:00 CRDT- 2020/10/19 06:01 PHST- 2020/06/06 00:00 [received] PHST- 2020/10/16 00:00 [accepted] PHST- 2020/10/20 06:00 [pubmed] PHST- 2022/02/15 06:00 [medline] PHST- 2020/10/19 06:01 [entrez] AID - 5929874 [pii] AID - 10.1093/infdis/jiaa662 [doi] PST - ppublish SO - J Infect Dis. 2021 Jun 15;223(12):2080-2089. doi: 10.1093/infdis/jiaa662.